Trials / Completed
CompletedNCT00721279
Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome
Sifrol Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary RLS
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 549 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of the Post Market Surveillance (PMS) study are to evaluate the treatment effect of pramipexole on Restless Legs Syndrome (RLS) severity as measured by International Restless Legs Rating Scale and Global Clinical Impression - Improvement, to evaluate the time to reaching maintenance dose of pramipexole
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sifrol® (pramipexole dihydrochloride) |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2008-10-01
- First posted
- 2008-07-24
- Last updated
- 2014-06-04
- Results posted
- 2010-01-08
Locations
127 sites across 1 country: Austria
Source: ClinicalTrials.gov record NCT00721279. Inclusion in this directory is not an endorsement.